RxDoctor Payments Data

Brent Jacobus, DO

Family Medicine · Crown Point, INNPI 1902807589

Payments from drug & device makers

$12,967in general payments, 2019–2025

Across 799 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Amgen$1K
  • Novo Nordisk$702
  • Otsuka America Pharmaceutical, Inc.$701
  • Lilly USA, LLC$599
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,931100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)165$2,627
AstraZeneca64$1,149
Amgen64$1,047
Novo Nordisk48$702
Otsuka America Pharmaceutical, Inc.35$701
Lilly USA, LLC38$599
Antares Pharma, Inc.38$596
Pfizer59$576
Takeda Pharmaceuticals U.S.A., Inc.33$474
Astellas Pharma US Inc21$381
Corium, LLC16$376
Alkermes, Inc.17$294
Biohaven Pharmaceutical Holding Company Ltd.13$219
GSK18$201
Boehringer Ingelheim11$190
Axsome Therapeutics, Inc.6$178
Orexo US, Inc.9$163
Supernus Pharmaceuticals, Inc.8$162
Idorsia Pharmaceuticals US Inc9$161
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$159
Sanofi-aventis U.S. LLC10$142
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$137
Merz North America, Inc.1$125
Amarin Pharma, Inc.9$124
Merck7$102
Almatica Pharma LLC4$92
Indivior Inc.4$72
Esperion Therapeutics, Inc.4$69
Vanda Pharmaceuticals Inc.2$63
Exact Sciences3$60
Clarus Therapeutics Inc.4$54
Johnson & Johnson4$52
Biohaven Pharmaceuticals, Inc.3$48
Novartis2$47
Itamar Medical Inc1$44
Bayer2$39
Avion Pharmaceuticals3$38
Bausch Health US, LLC2$37
Abbott1$37
Hikma Pharmaceuticals USA2$36
IBSA Pharma Inc.2$35
Sanofi Pasteur Inc.2$34
Biodelivery Sciences International, Inc.2$31
Phadia US Inc.2$31
Eisai Inc.2$30
Seqirus USA Inc2$29
Collegium Pharmaceutical, Inc.2$28
Ironwood Pharmaceuticals, Inc2$28
Fidia Pharma USA Inc.4$26
Ironshore Pharmaceuticals Inc.1$24
Jazz Pharmaceuticals Inc.1$22
Halozyme Inc1$21
Scilex Pharmaceuticals Inc.1$19
Upsher-smith Laboratories LLC1$19
Phathom Pharmaceuticals, Inc.1$19
Vertex1$18
Insulet Corporation1$18
Noven Therapeutics, LLC1$17
Edwards Lifesciences1$17
Adlon Therapeutics L.p.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,967 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$21,603
Medicare patients
63
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$33,278
VimpatLacosamide26$32,621
MounjaroTirzepatide19$23,389
XyostedTestosterone Enanthate31$18,928
JanuviaSitagliptin Phosphate11$14,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,101
NamzaricMemantine Hcl/Donepezil Hcl14$12,580
BelbucaBuprenorphine Hcl14$12,569
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl69$6,306
EntrestoSacubitril/Valsartan15$5,857
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen178$5,773
Lisdexamfetamine Dimesylate12$3,513
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine127$3,048
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen94$2,944
Lacosamide25$2,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$702$33,27839 claims
Lilly USA, LLCMounjaro$599$23,38919 claims
Antares Pharma, Inc.Xyosted$596$18,92831 claims
AbbVieNamzaric, Synthroid$2,627$14,71346 claims
MerckJanuvia$102$14,53811 claims
GSKTrelegy Ellipta$201$13,10120 claims
Collegium Pharmaceutical, Inc.Belbuca$28$12,56914 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$36$6,30669 claims
NovartisEntresto$47$5,85715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →